Skip to main content
Glama

Data Dallas

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.4/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare readOnly/openWorld/idempotent/non-destructive, so the bar is lower, but the description adds substantial behavioral context beyond that: mentions that unresolved identifiers are explicitly listed under `unresolved`, that ambiguous matches return `figi_candidates`, that LEI/FIGI enrichment degrades gracefully, and that each call cascades through multiple endpoints. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long but organized by supported types and complex enough to justify the length. It is mostly front-loaded with the core resolution behavior and 'Use FIRST' guidance. Some editorial asides, like 'which is the correct answer to an issuer name that does not identify a single bond,' add length without much new information, but most sentences earn their place.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite having no output schema, the description explains what the tool returns in practical terms: source-labelled identifiers, `figi_candidates` for ambiguous matches, an explicit `unresolved` field, RxNorm citations, and graceful degradation when enrichment sources fail. For a tool with this complexity, the behavioral coverage is strong and complete enough for an agent to call it correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%, and the input schema already documents both `type` and `value` thoroughly, including examples and the 'passed ENTITY NAME ONLY' guidance. The main description largely restates this information, so it adds limited meaning beyond the schema; the baseline of 3 is appropriate.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a precise verb+resource: resolve a user-spoken NAME to canonical/official identifiers. It differentiates the tool from siblings by noting it provides identifiers other tools require as input and by listing supported types (company, drug) with concrete output identifier kinds (CIK, ticker, LEI, FIGI, RxCUI).

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives explicit usage guidance: 'Use FIRST whenever you have a name but need an ID.' It also covers ambiguous cases and what happens then. However, it does not explicitly name alternative tools or state when not to use this tool, so it stops short of full when/when-not guidance.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Data Dallas toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4/5.0
Disambiguation4/5

Most tools have clearly distinct purposes, with a few overlapping pairs (e.g., ask_pipeworx vs ask_pipeworx_grounded, multiple polymarket tools) that could cause mild confusion, but descriptions adequately differentiate them.

Naming Consistency3/5

Tool names consistently use snake_case, but the verb_noun pattern is not consistently applied; some names are noun_noun (dallas_datasets, bet_research) or adjective_noun (ai_visibility_check), creating a mixed nomenclature.

Tool Count2/5

With 33 tools, the server exceeds the typical well-scoped range. While the broad data domain justifies many tools, the count feels heavy and would benefit from consolidation of related functions.

Completeness4/5

The tool set covers a wide array of domains (company data, drugs, economics, prediction markets, memory, subscriptions) with only minor gaps (e.g., no direct web search tool, as ask_pipeworx mostly covers it). Overall, it is comprehensive for its purpose.

Resources